Stealth Biotherapeutics' new drug application (NDA) for elamipretide has received a favourable vote from the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) for Barth syndrome.
Allay Therapeutics has announced a licensing agreement granting Maruishi Pharmaceutical exclusive rights to develop and commercialise ATX101, a non-opioid upivacaine-based drug, and other ultra-sustained analgesic implantable drug candidates for acute pain, in Japan.
Bio-Thera Solutions has received approval for the biosimilar of Actemra (tocilizumab), BAT1806, from the National Medical Products Administration (NMPA) of China.
Santhera Pharmaceuticals and ReveraGen BioPharma have announced the acceptance of vamorolone’s new drug application (NDA) for filing by the US Food and Drug Administration (FDA) to treat Duchenne muscular dystrophy (DMD).
Stealth BioTherapeutics has received Orphan Drug Designation from the US Food and Drug Administration (FDA) Office of Orphan Products Development for elamipretide to treat Duchenne muscular dystrophy (DMD) patients.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.